Literature DB >> 11107452

Timing of antitubulin therapy: does it matter?

R B Livingston.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 11107452     DOI： 10.3109/07357900009012214

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  1 in total

1.  SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.

Authors:  Robert B Livingston; William E Barlow; Joseph J Kash; Kathy S Albain; Julie R Gralow; Danika L Lew; Lawrence E Flaherty; Melanie E Royce; Gabriel N Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  2011-08-09       Impact factor: 4.872
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.